instruction
stringlengths 22
145
| input
stringclasses 1
value | answer
stringlengths 220
325
| text
stringlengths 382
597
|
|---|---|---|---|
The impact of side effects and adverse reactions on the median PFS for K Maintenance. | The median progression-free survival (PFS) for the treatment combination of K Maintenance from MUK Five was 11.9 months with a 95% Confidence Interval (CI) of (8.0, 13.1) (80% CI) <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for K Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of K Maintenance from MUK Five was 11.9 months with a 95% Confidence Interval (CI) of (8.0, 13.1) (80% CI) <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
The role of supportive care in improving the median PFS for K Maintenance. | The median progression-free survival (PFS) for the treatment combination of K Maintenance from MUK Five was 11.9 months with a 95% Confidence Interval (CI) of (8.0, 13.1) (80% CI) <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for K Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of K Maintenance from MUK Five was 11.9 months with a 95% Confidence Interval (CI) of (8.0, 13.1) (80% CI) <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for K Maintenance. | The median progression-free survival (PFS) for the treatment combination of K Maintenance from MUK Five was 11.9 months with a 95% Confidence Interval (CI) of (8.0, 13.1) (80% CI) <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for K Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of K Maintenance from MUK Five was 11.9 months with a 95% Confidence Interval (CI) of (8.0, 13.1) (80% CI) <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
The effect of concurrent health conditions on the median PFS for K Maintenance. | The median progression-free survival (PFS) for the treatment combination of K Maintenance from MUK Five was 11.9 months with a 95% Confidence Interval (CI) of (8.0, 13.1) (80% CI) <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for K Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of K Maintenance from MUK Five was 11.9 months with a 95% Confidence Interval (CI) of (8.0, 13.1) (80% CI) <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
Median PFS for No Maintenance? | The median progression-free survival (PFS) for the treatment combination of No Maintenance from MUK Five was 5.6 months with a 95% Confidence Interval (CI) of (4.8, 6.4) (80% CI) <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for No Maintenance?
### Response:
The median progression-free survival (PFS) for the treatment combination of No Maintenance from MUK Five was 5.6 months with a 95% Confidence Interval (CI) of (4.8, 6.4) (80% CI) <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
Comparison of the median PFS for No Maintenance with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of No Maintenance from MUK Five was 5.6 months with a 95% Confidence Interval (CI) of (4.8, 6.4) (80% CI) <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for No Maintenance with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of No Maintenance from MUK Five was 5.6 months with a 95% Confidence Interval (CI) of (4.8, 6.4) (80% CI) <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
The impact of patient characteristics on the median PFS for No Maintenance. | The median progression-free survival (PFS) for the treatment combination of No Maintenance from MUK Five was 5.6 months with a 95% Confidence Interval (CI) of (4.8, 6.4) (80% CI) <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for No Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of No Maintenance from MUK Five was 5.6 months with a 95% Confidence Interval (CI) of (4.8, 6.4) (80% CI) <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
The role of genetic factors in the median PFS for No Maintenance. | The median progression-free survival (PFS) for the treatment combination of No Maintenance from MUK Five was 5.6 months with a 95% Confidence Interval (CI) of (4.8, 6.4) (80% CI) <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for No Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of No Maintenance from MUK Five was 5.6 months with a 95% Confidence Interval (CI) of (4.8, 6.4) (80% CI) <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
The influence of previous treatments on the median PFS for No Maintenance. | The median progression-free survival (PFS) for the treatment combination of No Maintenance from MUK Five was 5.6 months with a 95% Confidence Interval (CI) of (4.8, 6.4) (80% CI) <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for No Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of No Maintenance from MUK Five was 5.6 months with a 95% Confidence Interval (CI) of (4.8, 6.4) (80% CI) <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
The effect of dosage and administration frequency on the median PFS for No Maintenance. | The median progression-free survival (PFS) for the treatment combination of No Maintenance from MUK Five was 5.6 months with a 95% Confidence Interval (CI) of (4.8, 6.4) (80% CI) <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for No Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of No Maintenance from MUK Five was 5.6 months with a 95% Confidence Interval (CI) of (4.8, 6.4) (80% CI) <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
The correlation between the median PFS for No Maintenance and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of No Maintenance from MUK Five was 5.6 months with a 95% Confidence Interval (CI) of (4.8, 6.4) (80% CI) <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for No Maintenance and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of No Maintenance from MUK Five was 5.6 months with a 95% Confidence Interval (CI) of (4.8, 6.4) (80% CI) <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for No Maintenance. | The median progression-free survival (PFS) for the treatment combination of No Maintenance from MUK Five was 5.6 months with a 95% Confidence Interval (CI) of (4.8, 6.4) (80% CI) <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for No Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of No Maintenance from MUK Five was 5.6 months with a 95% Confidence Interval (CI) of (4.8, 6.4) (80% CI) <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
The role of supportive care in improving the median PFS for No Maintenance. | The median progression-free survival (PFS) for the treatment combination of No Maintenance from MUK Five was 5.6 months with a 95% Confidence Interval (CI) of (4.8, 6.4) (80% CI) <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for No Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of No Maintenance from MUK Five was 5.6 months with a 95% Confidence Interval (CI) of (4.8, 6.4) (80% CI) <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for No Maintenance. | The median progression-free survival (PFS) for the treatment combination of No Maintenance from MUK Five was 5.6 months with a 95% Confidence Interval (CI) of (4.8, 6.4) (80% CI) <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for No Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of No Maintenance from MUK Five was 5.6 months with a 95% Confidence Interval (CI) of (4.8, 6.4) (80% CI) <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
The effect of concurrent health conditions on the median PFS for No Maintenance. | The median progression-free survival (PFS) for the treatment combination of No Maintenance from MUK Five was 5.6 months with a 95% Confidence Interval (CI) of (4.8, 6.4) (80% CI) <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for No Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of No Maintenance from MUK Five was 5.6 months with a 95% Confidence Interval (CI) of (4.8, 6.4) (80% CI) <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
Median PFS for Pomalidomide+Low-Dose Dexamethasone? | The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Low-Dose Dexamethasone from STRATUS was 4.6 months with a 95% Confidence Interval (CI) of (3.9, 4.9) <sup>[1](https://ashpublications.org/blood/article/128/4/497/35405/Safety-and-efficacy-of-pomalidomide-plus-low-dose)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Pomalidomide+Low-Dose Dexamethasone?
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Low-Dose Dexamethasone from STRATUS was 4.6 months with a 95% Confidence Interval (CI) of (3.9, 4.9) <sup>[1](https://ashpublications.org/blood/article/128/4/497/35405/Safety-and-efficacy-of-pomalidomide-plus-low-dose)</sup> |
|
Comparison of the median PFS for Pomalidomide+Low-Dose Dexamethasone with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Low-Dose Dexamethasone from STRATUS was 4.6 months with a 95% Confidence Interval (CI) of (3.9, 4.9) <sup>[1](https://ashpublications.org/blood/article/128/4/497/35405/Safety-and-efficacy-of-pomalidomide-plus-low-dose)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Pomalidomide+Low-Dose Dexamethasone with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Low-Dose Dexamethasone from STRATUS was 4.6 months with a 95% Confidence Interval (CI) of (3.9, 4.9) <sup>[1](https://ashpublications.org/blood/article/128/4/497/35405/Safety-and-efficacy-of-pomalidomide-plus-low-dose)</sup> |
|
The impact of patient characteristics on the median PFS for Pomalidomide+Low-Dose Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Low-Dose Dexamethasone from STRATUS was 4.6 months with a 95% Confidence Interval (CI) of (3.9, 4.9) <sup>[1](https://ashpublications.org/blood/article/128/4/497/35405/Safety-and-efficacy-of-pomalidomide-plus-low-dose)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Pomalidomide+Low-Dose Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Low-Dose Dexamethasone from STRATUS was 4.6 months with a 95% Confidence Interval (CI) of (3.9, 4.9) <sup>[1](https://ashpublications.org/blood/article/128/4/497/35405/Safety-and-efficacy-of-pomalidomide-plus-low-dose)</sup> |
|
The role of genetic factors in the median PFS for Pomalidomide+Low-Dose Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Low-Dose Dexamethasone from STRATUS was 4.6 months with a 95% Confidence Interval (CI) of (3.9, 4.9) <sup>[1](https://ashpublications.org/blood/article/128/4/497/35405/Safety-and-efficacy-of-pomalidomide-plus-low-dose)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Pomalidomide+Low-Dose Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Low-Dose Dexamethasone from STRATUS was 4.6 months with a 95% Confidence Interval (CI) of (3.9, 4.9) <sup>[1](https://ashpublications.org/blood/article/128/4/497/35405/Safety-and-efficacy-of-pomalidomide-plus-low-dose)</sup> |
|
The influence of previous treatments on the median PFS for Pomalidomide+Low-Dose Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Low-Dose Dexamethasone from STRATUS was 4.6 months with a 95% Confidence Interval (CI) of (3.9, 4.9) <sup>[1](https://ashpublications.org/blood/article/128/4/497/35405/Safety-and-efficacy-of-pomalidomide-plus-low-dose)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Pomalidomide+Low-Dose Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Low-Dose Dexamethasone from STRATUS was 4.6 months with a 95% Confidence Interval (CI) of (3.9, 4.9) <sup>[1](https://ashpublications.org/blood/article/128/4/497/35405/Safety-and-efficacy-of-pomalidomide-plus-low-dose)</sup> |
|
The effect of dosage and administration frequency on the median PFS for Pomalidomide+Low-Dose Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Low-Dose Dexamethasone from STRATUS was 4.6 months with a 95% Confidence Interval (CI) of (3.9, 4.9) <sup>[1](https://ashpublications.org/blood/article/128/4/497/35405/Safety-and-efficacy-of-pomalidomide-plus-low-dose)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Pomalidomide+Low-Dose Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Low-Dose Dexamethasone from STRATUS was 4.6 months with a 95% Confidence Interval (CI) of (3.9, 4.9) <sup>[1](https://ashpublications.org/blood/article/128/4/497/35405/Safety-and-efficacy-of-pomalidomide-plus-low-dose)</sup> |
|
The correlation between the median PFS for Pomalidomide+Low-Dose Dexamethasone and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Low-Dose Dexamethasone from STRATUS was 4.6 months with a 95% Confidence Interval (CI) of (3.9, 4.9) <sup>[1](https://ashpublications.org/blood/article/128/4/497/35405/Safety-and-efficacy-of-pomalidomide-plus-low-dose)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Pomalidomide+Low-Dose Dexamethasone and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Low-Dose Dexamethasone from STRATUS was 4.6 months with a 95% Confidence Interval (CI) of (3.9, 4.9) <sup>[1](https://ashpublications.org/blood/article/128/4/497/35405/Safety-and-efficacy-of-pomalidomide-plus-low-dose)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for Pomalidomide+Low-Dose Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Low-Dose Dexamethasone from STRATUS was 4.6 months with a 95% Confidence Interval (CI) of (3.9, 4.9) <sup>[1](https://ashpublications.org/blood/article/128/4/497/35405/Safety-and-efficacy-of-pomalidomide-plus-low-dose)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Pomalidomide+Low-Dose Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Low-Dose Dexamethasone from STRATUS was 4.6 months with a 95% Confidence Interval (CI) of (3.9, 4.9) <sup>[1](https://ashpublications.org/blood/article/128/4/497/35405/Safety-and-efficacy-of-pomalidomide-plus-low-dose)</sup> |
|
The role of supportive care in improving the median PFS for Pomalidomide+Low-Dose Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Low-Dose Dexamethasone from STRATUS was 4.6 months with a 95% Confidence Interval (CI) of (3.9, 4.9) <sup>[1](https://ashpublications.org/blood/article/128/4/497/35405/Safety-and-efficacy-of-pomalidomide-plus-low-dose)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Pomalidomide+Low-Dose Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Low-Dose Dexamethasone from STRATUS was 4.6 months with a 95% Confidence Interval (CI) of (3.9, 4.9) <sup>[1](https://ashpublications.org/blood/article/128/4/497/35405/Safety-and-efficacy-of-pomalidomide-plus-low-dose)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for Pomalidomide+Low-Dose Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Low-Dose Dexamethasone from STRATUS was 4.6 months with a 95% Confidence Interval (CI) of (3.9, 4.9) <sup>[1](https://ashpublications.org/blood/article/128/4/497/35405/Safety-and-efficacy-of-pomalidomide-plus-low-dose)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Pomalidomide+Low-Dose Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Low-Dose Dexamethasone from STRATUS was 4.6 months with a 95% Confidence Interval (CI) of (3.9, 4.9) <sup>[1](https://ashpublications.org/blood/article/128/4/497/35405/Safety-and-efficacy-of-pomalidomide-plus-low-dose)</sup> |
|
The effect of concurrent health conditions on the median PFS for Pomalidomide+Low-Dose Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Low-Dose Dexamethasone from STRATUS was 4.6 months with a 95% Confidence Interval (CI) of (3.9, 4.9) <sup>[1](https://ashpublications.org/blood/article/128/4/497/35405/Safety-and-efficacy-of-pomalidomide-plus-low-dose)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Pomalidomide+Low-Dose Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Low-Dose Dexamethasone from STRATUS was 4.6 months with a 95% Confidence Interval (CI) of (3.9, 4.9) <sup>[1](https://ashpublications.org/blood/article/128/4/497/35405/Safety-and-efficacy-of-pomalidomide-plus-low-dose)</sup> |
|
Median PFS for Lenalidomide Maintenance? | The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from Myeloma XI was 39 months with a 95% Confidence Interval (CI) of (36, 42) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Lenalidomide Maintenance?
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from Myeloma XI was 39 months with a 95% Confidence Interval (CI) of (36, 42) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
Comparison of the median PFS for Lenalidomide Maintenance with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from Myeloma XI was 39 months with a 95% Confidence Interval (CI) of (36, 42) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Lenalidomide Maintenance with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from Myeloma XI was 39 months with a 95% Confidence Interval (CI) of (36, 42) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The impact of patient characteristics on the median PFS for Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from Myeloma XI was 39 months with a 95% Confidence Interval (CI) of (36, 42) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from Myeloma XI was 39 months with a 95% Confidence Interval (CI) of (36, 42) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The role of genetic factors in the median PFS for Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from Myeloma XI was 39 months with a 95% Confidence Interval (CI) of (36, 42) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from Myeloma XI was 39 months with a 95% Confidence Interval (CI) of (36, 42) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The influence of previous treatments on the median PFS for Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from Myeloma XI was 39 months with a 95% Confidence Interval (CI) of (36, 42) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from Myeloma XI was 39 months with a 95% Confidence Interval (CI) of (36, 42) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The effect of dosage and administration frequency on the median PFS for Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from Myeloma XI was 39 months with a 95% Confidence Interval (CI) of (36, 42) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from Myeloma XI was 39 months with a 95% Confidence Interval (CI) of (36, 42) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The correlation between the median PFS for Lenalidomide Maintenance and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from Myeloma XI was 39 months with a 95% Confidence Interval (CI) of (36, 42) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Lenalidomide Maintenance and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from Myeloma XI was 39 months with a 95% Confidence Interval (CI) of (36, 42) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from Myeloma XI was 39 months with a 95% Confidence Interval (CI) of (36, 42) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from Myeloma XI was 39 months with a 95% Confidence Interval (CI) of (36, 42) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The role of supportive care in improving the median PFS for Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from Myeloma XI was 39 months with a 95% Confidence Interval (CI) of (36, 42) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from Myeloma XI was 39 months with a 95% Confidence Interval (CI) of (36, 42) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from Myeloma XI was 39 months with a 95% Confidence Interval (CI) of (36, 42) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from Myeloma XI was 39 months with a 95% Confidence Interval (CI) of (36, 42) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The effect of concurrent health conditions on the median PFS for Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from Myeloma XI was 39 months with a 95% Confidence Interval (CI) of (36, 42) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from Myeloma XI was 39 months with a 95% Confidence Interval (CI) of (36, 42) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
Median PFS for Observation? | The median progression-free survival (PFS) for the treatment combination of Observation from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (18, 22) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Observation?
### Response:
The median progression-free survival (PFS) for the treatment combination of Observation from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (18, 22) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
Comparison of the median PFS for Observation with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Observation from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (18, 22) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Observation with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of Observation from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (18, 22) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The impact of patient characteristics on the median PFS for Observation. | The median progression-free survival (PFS) for the treatment combination of Observation from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (18, 22) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Observation.
### Response:
The median progression-free survival (PFS) for the treatment combination of Observation from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (18, 22) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The role of genetic factors in the median PFS for Observation. | The median progression-free survival (PFS) for the treatment combination of Observation from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (18, 22) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Observation.
### Response:
The median progression-free survival (PFS) for the treatment combination of Observation from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (18, 22) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The influence of previous treatments on the median PFS for Observation. | The median progression-free survival (PFS) for the treatment combination of Observation from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (18, 22) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Observation.
### Response:
The median progression-free survival (PFS) for the treatment combination of Observation from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (18, 22) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The effect of dosage and administration frequency on the median PFS for Observation. | The median progression-free survival (PFS) for the treatment combination of Observation from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (18, 22) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Observation.
### Response:
The median progression-free survival (PFS) for the treatment combination of Observation from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (18, 22) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The correlation between the median PFS for Observation and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Observation from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (18, 22) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Observation and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of Observation from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (18, 22) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for Observation. | The median progression-free survival (PFS) for the treatment combination of Observation from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (18, 22) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Observation.
### Response:
The median progression-free survival (PFS) for the treatment combination of Observation from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (18, 22) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The role of supportive care in improving the median PFS for Observation. | The median progression-free survival (PFS) for the treatment combination of Observation from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (18, 22) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Observation.
### Response:
The median progression-free survival (PFS) for the treatment combination of Observation from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (18, 22) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for Observation. | The median progression-free survival (PFS) for the treatment combination of Observation from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (18, 22) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Observation.
### Response:
The median progression-free survival (PFS) for the treatment combination of Observation from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (18, 22) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The effect of concurrent health conditions on the median PFS for Observation. | The median progression-free survival (PFS) for the treatment combination of Observation from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (18, 22) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Observation.
### Response:
The median progression-free survival (PFS) for the treatment combination of Observation from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (18, 22) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
Median PFS for Cyclophosphamide+Bortezomib+Dexamethasone (CVD)? | The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Bortezomib+Dexamethasone (CVD) from Myeloma XI was 30 months with a 95% Confidence Interval (CI) of (25, 36) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Cyclophosphamide+Bortezomib+Dexamethasone (CVD)?
### Response:
The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Bortezomib+Dexamethasone (CVD) from Myeloma XI was 30 months with a 95% Confidence Interval (CI) of (25, 36) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
Comparison of the median PFS for Cyclophosphamide+Bortezomib+Dexamethasone (CVD) with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Bortezomib+Dexamethasone (CVD) from Myeloma XI was 30 months with a 95% Confidence Interval (CI) of (25, 36) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Cyclophosphamide+Bortezomib+Dexamethasone (CVD) with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Bortezomib+Dexamethasone (CVD) from Myeloma XI was 30 months with a 95% Confidence Interval (CI) of (25, 36) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The impact of patient characteristics on the median PFS for Cyclophosphamide+Bortezomib+Dexamethasone (CVD). | The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Bortezomib+Dexamethasone (CVD) from Myeloma XI was 30 months with a 95% Confidence Interval (CI) of (25, 36) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Cyclophosphamide+Bortezomib+Dexamethasone (CVD).
### Response:
The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Bortezomib+Dexamethasone (CVD) from Myeloma XI was 30 months with a 95% Confidence Interval (CI) of (25, 36) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The role of genetic factors in the median PFS for Cyclophosphamide+Bortezomib+Dexamethasone (CVD). | The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Bortezomib+Dexamethasone (CVD) from Myeloma XI was 30 months with a 95% Confidence Interval (CI) of (25, 36) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Cyclophosphamide+Bortezomib+Dexamethasone (CVD).
### Response:
The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Bortezomib+Dexamethasone (CVD) from Myeloma XI was 30 months with a 95% Confidence Interval (CI) of (25, 36) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The influence of previous treatments on the median PFS for Cyclophosphamide+Bortezomib+Dexamethasone (CVD). | The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Bortezomib+Dexamethasone (CVD) from Myeloma XI was 30 months with a 95% Confidence Interval (CI) of (25, 36) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Cyclophosphamide+Bortezomib+Dexamethasone (CVD).
### Response:
The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Bortezomib+Dexamethasone (CVD) from Myeloma XI was 30 months with a 95% Confidence Interval (CI) of (25, 36) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The effect of dosage and administration frequency on the median PFS for Cyclophosphamide+Bortezomib+Dexamethasone (CVD). | The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Bortezomib+Dexamethasone (CVD) from Myeloma XI was 30 months with a 95% Confidence Interval (CI) of (25, 36) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Cyclophosphamide+Bortezomib+Dexamethasone (CVD).
### Response:
The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Bortezomib+Dexamethasone (CVD) from Myeloma XI was 30 months with a 95% Confidence Interval (CI) of (25, 36) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The correlation between the median PFS for Cyclophosphamide+Bortezomib+Dexamethasone (CVD) and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Bortezomib+Dexamethasone (CVD) from Myeloma XI was 30 months with a 95% Confidence Interval (CI) of (25, 36) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Cyclophosphamide+Bortezomib+Dexamethasone (CVD) and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Bortezomib+Dexamethasone (CVD) from Myeloma XI was 30 months with a 95% Confidence Interval (CI) of (25, 36) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for Cyclophosphamide+Bortezomib+Dexamethasone (CVD). | The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Bortezomib+Dexamethasone (CVD) from Myeloma XI was 30 months with a 95% Confidence Interval (CI) of (25, 36) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Cyclophosphamide+Bortezomib+Dexamethasone (CVD).
### Response:
The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Bortezomib+Dexamethasone (CVD) from Myeloma XI was 30 months with a 95% Confidence Interval (CI) of (25, 36) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The role of supportive care in improving the median PFS for Cyclophosphamide+Bortezomib+Dexamethasone (CVD). | The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Bortezomib+Dexamethasone (CVD) from Myeloma XI was 30 months with a 95% Confidence Interval (CI) of (25, 36) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Cyclophosphamide+Bortezomib+Dexamethasone (CVD).
### Response:
The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Bortezomib+Dexamethasone (CVD) from Myeloma XI was 30 months with a 95% Confidence Interval (CI) of (25, 36) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for Cyclophosphamide+Bortezomib+Dexamethasone (CVD). | The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Bortezomib+Dexamethasone (CVD) from Myeloma XI was 30 months with a 95% Confidence Interval (CI) of (25, 36) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Cyclophosphamide+Bortezomib+Dexamethasone (CVD).
### Response:
The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Bortezomib+Dexamethasone (CVD) from Myeloma XI was 30 months with a 95% Confidence Interval (CI) of (25, 36) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The effect of concurrent health conditions on the median PFS for Cyclophosphamide+Bortezomib+Dexamethasone (CVD). | The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Bortezomib+Dexamethasone (CVD) from Myeloma XI was 30 months with a 95% Confidence Interval (CI) of (25, 36) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Cyclophosphamide+Bortezomib+Dexamethasone (CVD).
### Response:
The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Bortezomib+Dexamethasone (CVD) from Myeloma XI was 30 months with a 95% Confidence Interval (CI) of (25, 36) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
Median PFS for No CVD? | The median progression-free survival (PFS) for the treatment combination of No CVD from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (15, 28) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for No CVD?
### Response:
The median progression-free survival (PFS) for the treatment combination of No CVD from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (15, 28) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
Comparison of the median PFS for No CVD with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of No CVD from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (15, 28) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for No CVD with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of No CVD from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (15, 28) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The impact of patient characteristics on the median PFS for No CVD. | The median progression-free survival (PFS) for the treatment combination of No CVD from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (15, 28) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for No CVD.
### Response:
The median progression-free survival (PFS) for the treatment combination of No CVD from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (15, 28) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The role of genetic factors in the median PFS for No CVD. | The median progression-free survival (PFS) for the treatment combination of No CVD from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (15, 28) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for No CVD.
### Response:
The median progression-free survival (PFS) for the treatment combination of No CVD from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (15, 28) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The influence of previous treatments on the median PFS for No CVD. | The median progression-free survival (PFS) for the treatment combination of No CVD from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (15, 28) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for No CVD.
### Response:
The median progression-free survival (PFS) for the treatment combination of No CVD from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (15, 28) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The effect of dosage and administration frequency on the median PFS for No CVD. | The median progression-free survival (PFS) for the treatment combination of No CVD from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (15, 28) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for No CVD.
### Response:
The median progression-free survival (PFS) for the treatment combination of No CVD from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (15, 28) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The correlation between the median PFS for No CVD and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of No CVD from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (15, 28) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for No CVD and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of No CVD from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (15, 28) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for No CVD. | The median progression-free survival (PFS) for the treatment combination of No CVD from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (15, 28) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for No CVD.
### Response:
The median progression-free survival (PFS) for the treatment combination of No CVD from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (15, 28) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The role of supportive care in improving the median PFS for No CVD. | The median progression-free survival (PFS) for the treatment combination of No CVD from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (15, 28) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for No CVD.
### Response:
The median progression-free survival (PFS) for the treatment combination of No CVD from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (15, 28) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for No CVD. | The median progression-free survival (PFS) for the treatment combination of No CVD from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (15, 28) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for No CVD.
### Response:
The median progression-free survival (PFS) for the treatment combination of No CVD from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (15, 28) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
The effect of concurrent health conditions on the median PFS for No CVD. | The median progression-free survival (PFS) for the treatment combination of No CVD from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (15, 28) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for No CVD.
### Response:
The median progression-free survival (PFS) for the treatment combination of No CVD from Myeloma XI was 20 months with a 95% Confidence Interval (CI) of (15, 28) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/fulltext)</sup> |
|
Median PFS for Melflufen+Dexamethasone? | The median progression-free survival (PFS) for the treatment combination of Melflufen+Dexamethasone from OCEAN was 6.8 months with a 95% Confidence Interval (CI) of (5, 8.5) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Melflufen+Dexamethasone?
### Response:
The median progression-free survival (PFS) for the treatment combination of Melflufen+Dexamethasone from OCEAN was 6.8 months with a 95% Confidence Interval (CI) of (5, 8.5) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> |
|
Comparison of the median PFS for Melflufen+Dexamethasone with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Melflufen+Dexamethasone from OCEAN was 6.8 months with a 95% Confidence Interval (CI) of (5, 8.5) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Melflufen+Dexamethasone with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of Melflufen+Dexamethasone from OCEAN was 6.8 months with a 95% Confidence Interval (CI) of (5, 8.5) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> |
|
The impact of patient characteristics on the median PFS for Melflufen+Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Melflufen+Dexamethasone from OCEAN was 6.8 months with a 95% Confidence Interval (CI) of (5, 8.5) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Melflufen+Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Melflufen+Dexamethasone from OCEAN was 6.8 months with a 95% Confidence Interval (CI) of (5, 8.5) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> |
|
The role of genetic factors in the median PFS for Melflufen+Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Melflufen+Dexamethasone from OCEAN was 6.8 months with a 95% Confidence Interval (CI) of (5, 8.5) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Melflufen+Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Melflufen+Dexamethasone from OCEAN was 6.8 months with a 95% Confidence Interval (CI) of (5, 8.5) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> |
|
The influence of previous treatments on the median PFS for Melflufen+Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Melflufen+Dexamethasone from OCEAN was 6.8 months with a 95% Confidence Interval (CI) of (5, 8.5) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Melflufen+Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Melflufen+Dexamethasone from OCEAN was 6.8 months with a 95% Confidence Interval (CI) of (5, 8.5) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> |
|
The effect of dosage and administration frequency on the median PFS for Melflufen+Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Melflufen+Dexamethasone from OCEAN was 6.8 months with a 95% Confidence Interval (CI) of (5, 8.5) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Melflufen+Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Melflufen+Dexamethasone from OCEAN was 6.8 months with a 95% Confidence Interval (CI) of (5, 8.5) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> |
|
The correlation between the median PFS for Melflufen+Dexamethasone and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Melflufen+Dexamethasone from OCEAN was 6.8 months with a 95% Confidence Interval (CI) of (5, 8.5) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Melflufen+Dexamethasone and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of Melflufen+Dexamethasone from OCEAN was 6.8 months with a 95% Confidence Interval (CI) of (5, 8.5) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for Melflufen+Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Melflufen+Dexamethasone from OCEAN was 6.8 months with a 95% Confidence Interval (CI) of (5, 8.5) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Melflufen+Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Melflufen+Dexamethasone from OCEAN was 6.8 months with a 95% Confidence Interval (CI) of (5, 8.5) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> |
|
The role of supportive care in improving the median PFS for Melflufen+Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Melflufen+Dexamethasone from OCEAN was 6.8 months with a 95% Confidence Interval (CI) of (5, 8.5) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Melflufen+Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Melflufen+Dexamethasone from OCEAN was 6.8 months with a 95% Confidence Interval (CI) of (5, 8.5) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for Melflufen+Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Melflufen+Dexamethasone from OCEAN was 6.8 months with a 95% Confidence Interval (CI) of (5, 8.5) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Melflufen+Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Melflufen+Dexamethasone from OCEAN was 6.8 months with a 95% Confidence Interval (CI) of (5, 8.5) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> |
|
The effect of concurrent health conditions on the median PFS for Melflufen+Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Melflufen+Dexamethasone from OCEAN was 6.8 months with a 95% Confidence Interval (CI) of (5, 8.5) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Melflufen+Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Melflufen+Dexamethasone from OCEAN was 6.8 months with a 95% Confidence Interval (CI) of (5, 8.5) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> |
|
Median PFS for Pomalidomide+Dexamethasone? | The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from OCEAN was 4.9 months with a 95% Confidence Interval (CI) of (4.2, 5.7) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Pomalidomide+Dexamethasone?
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from OCEAN was 4.9 months with a 95% Confidence Interval (CI) of (4.2, 5.7) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> |
|
Comparison of the median PFS for Pomalidomide+Dexamethasone with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from OCEAN was 4.9 months with a 95% Confidence Interval (CI) of (4.2, 5.7) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Pomalidomide+Dexamethasone with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from OCEAN was 4.9 months with a 95% Confidence Interval (CI) of (4.2, 5.7) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> |
|
The impact of patient characteristics on the median PFS for Pomalidomide+Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from OCEAN was 4.9 months with a 95% Confidence Interval (CI) of (4.2, 5.7) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Pomalidomide+Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from OCEAN was 4.9 months with a 95% Confidence Interval (CI) of (4.2, 5.7) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> |
|
The role of genetic factors in the median PFS for Pomalidomide+Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from OCEAN was 4.9 months with a 95% Confidence Interval (CI) of (4.2, 5.7) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Pomalidomide+Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from OCEAN was 4.9 months with a 95% Confidence Interval (CI) of (4.2, 5.7) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> |
|
The influence of previous treatments on the median PFS for Pomalidomide+Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from OCEAN was 4.9 months with a 95% Confidence Interval (CI) of (4.2, 5.7) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Pomalidomide+Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from OCEAN was 4.9 months with a 95% Confidence Interval (CI) of (4.2, 5.7) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> |
|
The effect of dosage and administration frequency on the median PFS for Pomalidomide+Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from OCEAN was 4.9 months with a 95% Confidence Interval (CI) of (4.2, 5.7) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Pomalidomide+Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from OCEAN was 4.9 months with a 95% Confidence Interval (CI) of (4.2, 5.7) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> |
|
The correlation between the median PFS for Pomalidomide+Dexamethasone and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from OCEAN was 4.9 months with a 95% Confidence Interval (CI) of (4.2, 5.7) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Pomalidomide+Dexamethasone and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from OCEAN was 4.9 months with a 95% Confidence Interval (CI) of (4.2, 5.7) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for Pomalidomide+Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from OCEAN was 4.9 months with a 95% Confidence Interval (CI) of (4.2, 5.7) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Pomalidomide+Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from OCEAN was 4.9 months with a 95% Confidence Interval (CI) of (4.2, 5.7) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> |
|
The role of supportive care in improving the median PFS for Pomalidomide+Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from OCEAN was 4.9 months with a 95% Confidence Interval (CI) of (4.2, 5.7) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Pomalidomide+Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from OCEAN was 4.9 months with a 95% Confidence Interval (CI) of (4.2, 5.7) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for Pomalidomide+Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from OCEAN was 4.9 months with a 95% Confidence Interval (CI) of (4.2, 5.7) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Pomalidomide+Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from OCEAN was 4.9 months with a 95% Confidence Interval (CI) of (4.2, 5.7) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> |
|
The effect of concurrent health conditions on the median PFS for Pomalidomide+Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from OCEAN was 4.9 months with a 95% Confidence Interval (CI) of (4.2, 5.7) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Pomalidomide+Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from OCEAN was 4.9 months with a 95% Confidence Interval (CI) of (4.2, 5.7) <sup>[1](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00381-1/fulltext)</sup> |
|
Median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd)? | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from EQUULEUS was 8.8 months with a 95% Confidence Interval (CI) of (4.6, 15.4) <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd)?
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from EQUULEUS was 8.8 months with a 95% Confidence Interval (CI) of (4.6, 15.4) <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> |
|
Comparison of the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from EQUULEUS was 8.8 months with a 95% Confidence Interval (CI) of (4.6, 15.4) <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from EQUULEUS was 8.8 months with a 95% Confidence Interval (CI) of (4.6, 15.4) <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> |
|
The impact of patient characteristics on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd). | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from EQUULEUS was 8.8 months with a 95% Confidence Interval (CI) of (4.6, 15.4) <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from EQUULEUS was 8.8 months with a 95% Confidence Interval (CI) of (4.6, 15.4) <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> |
|
The role of genetic factors in the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd). | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from EQUULEUS was 8.8 months with a 95% Confidence Interval (CI) of (4.6, 15.4) <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from EQUULEUS was 8.8 months with a 95% Confidence Interval (CI) of (4.6, 15.4) <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> |
|
The influence of previous treatments on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd). | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from EQUULEUS was 8.8 months with a 95% Confidence Interval (CI) of (4.6, 15.4) <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from EQUULEUS was 8.8 months with a 95% Confidence Interval (CI) of (4.6, 15.4) <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> |
|
The effect of dosage and administration frequency on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd). | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from EQUULEUS was 8.8 months with a 95% Confidence Interval (CI) of (4.6, 15.4) <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from EQUULEUS was 8.8 months with a 95% Confidence Interval (CI) of (4.6, 15.4) <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> |
|
The correlation between the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from EQUULEUS was 8.8 months with a 95% Confidence Interval (CI) of (4.6, 15.4) <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from EQUULEUS was 8.8 months with a 95% Confidence Interval (CI) of (4.6, 15.4) <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd). | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from EQUULEUS was 8.8 months with a 95% Confidence Interval (CI) of (4.6, 15.4) <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from EQUULEUS was 8.8 months with a 95% Confidence Interval (CI) of (4.6, 15.4) <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> |
Subsets and Splits